MedPath

Comparision study of two poly herbal formulation in type 2 diabetes mellitus (prameha)

Phase 2/3
Not yet recruiting
Conditions
Type 2 diabetes mellitus without complications. Ayurveda Condition: PRAMEHAH,
Registration Number
CTRI/2023/06/053817
Lead Sponsor
NATIONAL INSTITUTE OF AYURVEDA,DEEMED TO BE UNIVERSITY
Brief Summary

·       This study is a single centre, openlabel, randomized, interventional, and comparing the safety and efficacy ofTriphalÄdi Kaá¹£Äya50 ml & MustÄdi  Kaá¹£Äya50ml.

·       Procedure protocol will be followed:

·       Patients who fulfill the diagnosticcriteria of Pitta-kaphaja *Prameha* explained in *Ä€yurvedika*classics and Diagnostic criteria of Diabetes MellitusType-IIICMR guidelines will be selected from nia hospital.

·       Patients will be divided in twogroups, each group contains 30 patients, one group will received TriphalÄdiKaá¹£Äya (50 ml) and another group will received MustÄdi  Kaá¹£Äya (50ml).

·       Allpatients will be followed up fortnightly for 60 days.

·       The full details of history &physical examination of patient will be recorded as per the Performa.

·       Assessment of Subjective Parameters  and objective parameters will be done on 15thday, 30th day, 45th day, 60th day afterinitial assessment.

·       The primary outcome measures will be Improvement in sign and symptoms of the disease andchanges in investigation parameters i.e. FBS, PPBS, HbA1c and Urine R/M andthe other Subjective parameters Improvement in quality of life as per *Ä€yurvedika* text in terms of *Agni, Bala, Nidra, Kosthasuddhi* etc. and changes in other Lab. Investigation  LFT, RFT,CBC,ESR,LIPID PROFILE etc.

·       Resultswill be analysed with appropriate statistical tests as follow - SubjectiveParameters – Wilcoxon’s paired rank test and Mann Whitney U test.

·        Objective Parameters – Paired ‘t’ test andunpaired ‘t’ test.

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
All
Target Recruitment
60
Inclusion Criteria
  • INCLUSION CRITERIA:– 1. Patients willing to sign Consent Form for the clinical trial. 2. Patients between the age group of 18-70 years, irrespective of sex, caste, religion and socioeconomic status. 3. Patients who fulfill the diagnostic criteria of Pitta-kaphaja Prameha explained in Ä€yurvedika classics and Diagnostic criteria of Diabetes Mellitus Type-II ICMR guidelines 2018.
  • ï‚·Symptoms of diabetes plus casual or random plasma glucose ≥ 200 mg/dl (Casual means without regard to time of last meal). ï‚·PPBS >180mg/dl with upper range of 300 mg/dl. ï‚·Fasting plasma glucose ≥ 126 mg/dl with upper range of 200 mg/dl. ï‚·Glycated Haemoglobin ≥ 6.5% with upper range of 11.5%.
Exclusion Criteria
  • EXCLUSION CRITERIA:- 1.Patients below 18 and after 70 years.
  • 3.Patients with complications and contraindicated for treatment in Ä€yurvedika and modern texts.
  • 4.Patients of Diabetes Mellitus Type1 5.Patients on allopathic anti-diabetic drug.
  • 6.Malignancy, other endocrinal disorders, chronic infectious diseases etc.
  • 7.Pregnant and lactating mother.
  • Patients having any serious illness like cardiovascular diseases, renal diseases etc.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Primary outcome:60 DAYS((BEFORE TREATMENT AND AFTER TREATMENT))
Improvement in sign and symptoms of the disease and changes in investigation parameters i.e. FBS, PPBS, HbA1c and Urine R/M60 DAYS((BEFORE TREATMENT AND AFTER TREATMENT))
Secondary Outcome Measures
NameTimeMethod
Secondary outcome:Improvement in quality of life as per Āyurvedika text in terms of Agni, Bala, Nidra, Kostha suddhi etc. and changes in other Lab. Investigation LFT, RFT, CBC,ESR,LIPID PROFILE etc.

Trial Locations

Locations (1)

National Institute of Ayurveda Hospital,jorawar singh gate,Jaipur

🇮🇳

Jaipur, RAJASTHAN, India

National Institute of Ayurveda Hospital,jorawar singh gate,Jaipur
🇮🇳Jaipur, RAJASTHAN, India
DrAbhinesh
Principal investigator
8432688966
kumawatabhinesh@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.